The Wellness Pivot: Tooru PLC Completes Transformation
Tooru PLC’s latest RNS isn’t just annual results – it’s a birth certificate. The former RiverFort Global Opportunities has shed its investment company skin to emerge as a health and wellness operator. This strategic metamorphosis, finalised through the S-Ventures acquisition, marks one of the more intriguing AIM transformations we’ve seen recently.
Why the Radical Shift?
The board confronted a harsh reality: small investment vehicles on AIM were becoming investor kryptonite. Trading at a persistent discount to NAV (74% at last count), they needed to create tangible value. Enter S-Ventures – a profitable foothold in the booming £150bn+ global wellness market.
The mechanics were decisive:
- Portfolio liquidation: £2.2m debt/equity portfolio redemption in March 2024 to fund the pivot
- Strategic divorce: Termination of RiverFort Global Capital advisory contract
- Suspension play: AIM rules triggered suspension during the reverse takeover (RTO) process
- Re-admission: Enlarged group restored to trading on 29th May 2025
The New Tooru: Unpacking the Assets
S-Ventures brings four established revenue streams:
1. We Love Purely
Plantain chip disruptors targeting the £1.3bn UK healthy snacking market. Gluten-free, vegan, no palm oil – textbook modern category positioning.
2. Pulsin
Beyond its consumer brand, this is a hidden gem: a plant-based nutrition manufacturer with third-party contracting capabilities. Facility in Gloucester provides operational leverage.
3. Juvela
The cash flow stabiliser. Over 25 years in prescription gluten-free foods with NHS contracts. Combines essential service resilience with retail presence.
4. Market Rocket
The digital accelerator. Certified Amazon/Meta/Google partner serving brands like JCB and Calvin Klein. Critical for scaling the other subsidiaries’ e-commerce.
Critically, these aren’t hopeful start-ups. H1 2024 showed £7.2m revenue with £800k EBITDA – immediately earnings-accretive.
Financial Health Check
The 2024 numbers reflect transition pains:
- £1.05m net loss (2023: £5.34m loss)
- NAV down 18% to £4.2m
- Cash position healthy at £2.35m pre-acquisition
Post-deal structure reveals clever financing:
- Equity consideration: 466.7m shares issued to S-Ventures @ 0.75p (£3.5m value)
- Creditor settlement: 356.3m shares issued @ 0.75p (£2.67m)
- Cash raise: £500k via 66.7m new shares @ 0.75p
The Road Ahead: Questions Investors Should Ask
Management’s playbook appears clear:
- Integration: Cross-selling between Juvela’s NHS access and Purely/Pulsin products
- E-commerce scaling: Leveraging Market Rocket’s expertise across brands
- Platform acquisitions: Explicitly targeting bolt-ons in wellness
But caveats exist:
- Cash runway projection to June 2026 assumes successful new product launches
- Board admits “reasonable worst-case scenario” may require additional funding
- Director stakes remain modest (Lee: 0.59%, Haydn-Slater: 2.58%)
The Verdict?
This is more than a rebrand – it’s a complete corporate identity transplant. The S-Ventures assets provide immediate revenue diversity in structurally growing markets. Execution risk remains, but for investors weary of the “AIM discount discount,” Tooru now offers something rare: tangible products in tangible markets. The wellness pivot looks well-timed – now we watch for commercial integration. One to monitor closely.
